Drug testing billing for independent toxicology labs, pain management practices with in-office labs, and addiction treatment programs.
A drug test pays once per patient per date of service, and only when an individualized order backs it. Toxicology revenue leaks at that seam: a cup billed as five units, a definitive panel run on a standing order, a waived test sent to Medicare without QW, a specimen that never left the LIS. Luxen codes, submits and works every presumptive and definitive claim inside your LIS and EHR, with a BAA signed before we see a single record.
On this page
Toxicology billing services code, submit and follow up presumptive (80305 to 80307) and definitive (G0480 to G0483, G0659) drug testing claims, matching each claim to an individualized order and the Medicare LCD. In the Luxen claim audit, 17% of definitive drug testing claims lacked an individualized order.
We bill drug testing for four kinds of practices, and the claim looks different in each.
Service lines: presumptive screening, definitive testing, alcohol biomarkers, and the visits and injections on the same patients.
Toxicology revenue leaks through unpaid units, orders that fail review and results that never become claims. Dollar figures are 2026 Florida Medicaid laboratory fee schedule amounts (AHCA) or Luxen claim audit data. Every row is a check in our denials and AR recovery work.
| Scenario | Codes | What goes wrong | $ at stake per claim | Luxen audit finding |
|---|---|---|---|---|
| Cup read in the office, second screen sent to a reference lab | 80305 plus 80307 | Medicare pays 1 presumptive test per patient per date of service across all billing providers, so one line denies | $37.28 per 80307 line | Presumptive and reference lab dates of service compared before submission |
| Definitive panel run on every patient | G0482, G0483 | Standing order, no individualized reason by drug class; denied or recouped on review | A denied definitive drug testing claim cost a median $121 | 17% of definitive drug testing claims lacked an individualized order |
| Presumptive test billed per drug class or per device | 80305 to 80307 with 2 or more units | Codes are reported once per date of service with one unit | $7.56 per 80305 date of service, extra units unpaid | Presumptive tests billed with more than one unit caused 8% of toxicology denials |
| Result in the LIS, no charge created | 80307, G0480 | Accession never crosses into billing | $37.28 per missed 80307 | Accession logs reconciled to claims weekly |
| OTP patient tested during a billed bundle week | G0480 with G2067 | Toxicology testing is included in the weekly bundle | Full definitive line | Bundle weeks matched against separate lab claims |
Medicare and many other payers use different definitive codes, so our certified medical coders set the code set per payer before the first claim goes out.
Each code covers any number of drug classes and devices, includes sample validation, and is reported per date of service (CMS CY2017 CLFS determinations).
| Code | Method | Typical setting | Florida Medicaid 2026 |
|---|---|---|---|
| 80305 | Read by direct optical observation only | Point-of-care cup or dipstick | $7.56 |
| 80306 | Read by instrument assisted direct optical observation | Cup or strip read by a reader | $10.28 |
| 80307 | By instrument chemistry analyzers | Immunoassay analyzer in a practice or reference lab | $37.28 |
| Code | Drug classes per day | Note |
|---|---|---|
| G0480 | 1 to 7 | Includes specimen validity testing |
| G0481 | 8 to 14 | Includes specimen validity testing |
| G0482 | 15 to 21 | Includes specimen validity testing |
| G0483 | 22 or more | Includes specimen validity testing |
| G0659 | Any number | Methods without drug-specific calibration or matrix-matched quality control |
Descriptors: CMS CY2019 CLFS determinations. WPS lists CPT 80320 to 80377 as non-covered codes for Medicare (L34645).
Many Medicaid and commercial plans pay definitive testing per drug class with CPT 80320 to 80377. Florida Medicaid pays 80320 (alcohols) at $12.04 and 80324 (amphetamines, 1 or 2) at $15.56, so labs in Florida medical billing price panels differently than under one G code.
Most drug testing denials and recoupments come from the order, not the code. Testing must be ordered by the practitioner treating the patient who uses the result (42 CFR 410.32).
| Medicare contractor | LCD | Jurisdiction |
|---|---|---|
| CGS | L36029 | J15: Kentucky, Ohio |
| Palmetto GBA | L35724 | JJ and JM, including Georgia, Tennessee, Virginia and West Virginia |
| Noridian | L36668 | JE and JF |
| WPS | L34645 | J5 and J8 |
| Novitas | L35006 | JH and JL |
| First Coast | L36393 | JN: Florida, Puerto Rico, US Virgin Islands |
Labs serving Kentucky medical billing clients follow CGS L36029, and those in West Virginia medical billing follow Palmetto L35724.
| Risk group | Presumptive and definitive testing, each |
|---|---|
| Low risk | No more than 2 times in a rolling 365 days |
| Moderate risk | No more than 2 times in a rolling 180 days |
| High risk | No more than 3 times in a rolling 90 days |
Source: L35724. Testing beyond these limits needs documented reasons in the chart, which is why our eligibility and prior authorization team checks prior test dates before collection.
L36029 covers definitive testing to identify a negative, or confirm a positive, presumptive result that is inconsistent with the patient's self-report, presentation, history or prescribed medication. Doing both a point-of-care presumptive test and a reference lab presumptive immunoassay is not reasonable and necessary (L36668).
Who bills a specimen, and on which claim, decides whether it pays.
Medicare counts toxicology testing as an OUD treatment service (42 CFR 410.67), and the G2067 weekly bundle includes toxicology testing, if performed (Claims Processing Manual, Chapter 39). A program billing the bundle does not add G0480 or 80307 for tests it runs that week.
A pain or addiction practice with a waived certificate bills 80305 with QW. It chooses per patient whether presumptive testing happens in the office or at the reference lab, never both on one date. CDC's 2022 guideline asks clinicians prescribing opioids for subacute or chronic pain to weigh the benefits and risks of toxicology testing (CDC Recommendation 10).
The lab bills what it performs, on the collection date, under the ordering practitioner's NPI. It keeps the order and proof the claim matches it (42 CFR 410.32(d)(2)), so a one-panel order form puts recoupment risk on the lab.
Federal EKRA (18 U.S.C. 220) bars paying for referrals to laboratories, recovery homes and clinical treatment facilities, with fines as high as $200,000, 10 years in prison, or both, per occurrence (18 U.S.C. 220). Florida's Patient Brokering Act adds a state felony for commissions or kickbacks tied to patient referrals, including to licensed substance abuse providers (Fla. Stat. 817.505).
Presumptive codes cover any number of drug classes and are reported with one unit per date of service (NCCI Policy Manual 2026, Chapter 10). Presumptive tests billed with more than one unit caused 8% of toxicology denials (Luxen claim audit).
Routine standing orders for all patients in a practice are not reasonable and necessary (L35724). Payment made on those orders is recouped on review, and a denied definitive drug testing claim cost a median $121 in the Luxen claim audit. 17% of definitive drug testing claims lacked an individualized order across 5,600 toxicology claims (Luxen claim audit).
Validity testing on urine specimens used for drug testing is not separately billed (NCCI Policy Manual 2026); it is already part of every presumptive and definitive descriptor. Coding and modifier errors caused 21% of denials (Luxen claim audit).
Waived tests need the QW modifier on the HCPCS code under Claims Processing Manual Chapter 16, section 70.8 (MM14476), and the CLIA number on the claim. Without them the line rejects. The QW modifier was missing on 12% of CLIA-waived presumptive claims (Luxen claim audit).
We run the revenue cycle from eligibility to zero balance inside the practice management system you already use. How full-service billing works.
Certified coders review charges against your documentation and payer rules before the claim goes out, so the denial is prevented rather than appealed. Medical coding.
Aged and denied claims are worked to resolution, then the upstream cause is fixed so the same claims stop coming back. Denials and AR recovery.
Benefits are verified and authorizations secured before the appointment, which is the cheapest place in the cycle to stop a denial. Eligibility and prior authorization.
Statements, balance questions and payment plans are handled by the same team that worked the claim. Patient billing.
Payer enrollment and re-credentialing are tracked through to approval, so a lapsed credential never quietly stops payment. Credentialing.
A HIPAA-trained front-office assistant working inside your EHR on calls, scheduling, intake and referrals, alongside the billing team. Medical virtual assistant.
Toxicology billing runs across two systems: the LIS that holds the accession and result, and the EHR that holds the order and the reason for it. We work in lab systems such as CGM LABDAQ, Orchard Harvest, Dendi and Clinisys, and in the EHRs pain and addiction practices use, including Epic, athenaOne, eClinicalWorks, NextGen, ModMed and Kipu. We reconcile accessions to claims and pull orders from the chart when a payer asks. No migration.
2 weeks
from a signed BAA to our team working your claims
About 3 weeks
to the first recovered payments on aged AR
20+ years
combined billing and coding experience
Presumptive and definitive testing claims were submitted without a consistent review of the order and documented medical need. Luxen rebuilt the process, reduced toxicology denials from 23% to 7%, and recovered $94,600.
Laboratory Director, clinical toxicology practice
Our specimen log showed completed tests that never reached billing. Luxen reconciled every accession against the claim file, identified 312 missed tests, and recovered $46,100 in one quarter.
Billing Manager, independent toxicology laboratory
Full engagements are written up in our dental practice case study and our ambulance billing case study.
Section 6226 of the Consolidated Appropriations Act, 2026 (February 3, 2026) left no phased-in reduction for CY 2026 (MM14476). From 2027 through 2029, CLFS payments may not be reduced by more than 15% per year, and the latest private payer data reporting period ran May 1 to July 31, 2026, using January 1 to June 30, 2025 data (CMS CLFS).
Patients usually pay nothing for Medicare-covered diagnostic lab tests (Medicare.gov), and neither the Part B deductible nor coinsurance applies on assigned lab claims (Claims Processing Manual, Chapter 16).
When a test is expected to be denied as not reasonable and necessary, the patient signs an ABN, Form CMS-R-131, before the specimen is collected (CMS ABN). The claim carries GA when an ABN is on file or GZ when it is not (MLN006266).
Uninsured and self-pay patients get a good faith estimate (45 CFR 149.610). In our patient billing work, statements plus text reminders raised patient collections 22% across 14 practices (Luxen client data).
3% to 6% of collections
Luxen's pricing generally falls between 3% and 6% of collections, depending on claim volume, specialty, payer mix, and how much of the revenue cycle your practice hands over.
Higher-volume practices usually land toward the lower end. Smaller or more complex practices land higher because there is more work per account. There is no setup fee and no exit fee, and the agreement runs month to month with 30 days notice.
A lower fee attached to weak billing is still expensive. The number that matters is what your collections do after you hire someone.
Luxen charges 3% to 6% of collections, set by payer mix, definitive testing volume and how many orders need review. No setup or exit fee.
| Service line | Monthly collections | Luxen at 3% | Luxen at 6% |
|---|---|---|---|
| Presumptive testing | $25,000 | $750 | $1,500 |
| Definitive testing | $100,000 | $3,000 | $6,000 |
| Total | $125,000 | $3,750 | $7,500 |
| Cost | In-house | Luxen |
|---|---|---|
| Monthly | $9,875 (7.9% of collections) | $3,750 to $7,500 |
| Annual | $118,500 | $45,000 to $90,000 |
| When a biller leaves | Open biller roles took a median 67 days to fill | No gap in coverage |
| Terms | Salaries, benefits, LIS billing module | Month to month, 30 days notice |
Fully loaded in-house billing cost 7.9% of collections for practices under $2M, across 96 practices that shared payroll data (Luxen billing reviews).
| Partner type | Drug testing code depth | Order and LCD review | Reporting | Terms |
|---|---|---|---|---|
| In-house biller | Depends on one person | Rarely before submission | Built by your staff | Payroll and turnover |
| Generalist billing company | Physician CPT focus | Usually after denial | Standard aging reports | Often annual terms |
| Specialty lab billing company | G code and per-class experience | Varies | Varies | Varies, some charge setup fees |
| EHR or LIS vendor RCM | Tied to vendor edits | Limited | Inside the vendor platform | Bundled with software |
| Luxen | Certified coders for presumptive, definitive and per-class codes | Before submission | Monthly denials, AR and unbilled specimens | Month to month, 30 days notice |
Compare medical billing companies on these points, or see what full-service medical billing covers.
A 30-minute look at your AR ageing, denial reasons and payer mix. You leave knowing what is recoverable, what we would work first and what it would cost.
We sign a business associate agreement before anyone touches your system. Your named team then works inside the practice management system and clearinghouse you already use. Nothing is migrated, and claims are being worked within two weeks of the signed BAA.
Aged and denied claims come first because that is revenue you have already earned. Most practices see the first recovered payments inside three weeks.
Once the backlog is moving, we take over the agreed part of the daily cycle: eligibility, coding review, submission, posting, denials and patient balances.
You know who owns your claims. The team works inside the practice management system and EHR you already run, with no migration.
Claims are coded by certified coders against your documentation and payer rules. Automation handles the repetitive checks so people spend their time on the claims that need judgment.
We sign a business associate agreement before accessing protected health information, and access is limited to the named people on your account.
We look at your AR ageing, volume, payer mix and denial profile first, then tell you what we believe is recoverable and what it would cost.
A billing company is a poor fit if you are not willing to share visibility into your billing, if the vendor uses a rotating pool of people who never learn your practice, or if it cannot explain why your claims are being denied. Be wary of anyone promising large collection increases before they have seen your AR ageing. The right partner makes your revenue cycle more visible, not less.
Presumptive drug screens use CPT 80305, 80306 or 80307, depending on the method, once per date of service. Medicare definitive testing is reported with G0480 to G0483, tiered at 1 to 7, 8 to 14, 15 to 21 or 22 or more drug classes, or G0659. Many Medicaid and commercial plans pay definitive testing per drug class with 80320 to 80377.
Luxen charges 3% to 6% of collections, with no setup or exit fee. A lab collecting $125,000 a month would pay $3,750 to $7,500, depending mostly on definitive testing volume and payer mix. Fully loaded in-house billing cost 7.9% of collections for practices under $2M.
About 2 weeks from signed BAA to working claims: median time from signed BAA to first claims worked was 9 business days (Luxen client data). We work the oldest AR first, and first recovered payments arrived a median of 17 days after work began. Contracts are month to month with 30 days notice.
Yes. We work inside your LIS, such as CGM LABDAQ or Orchard Harvest, and your EHR. Switching hurts cash: 38% had changed EHR or practice management system in the past five years, and 71% of those said collections dipped for at least six months (Luxen Practice Manager Survey 2026).
Not for Medicare weeks it bills a bundle. 42 CFR 410.67 lists toxicology testing as an OUD treatment service, and the G2067 weekly bundle includes toxicology testing, if performed. A separate G0480 or 80307 line from the program for that week is not separately payable, so we match bundle weeks against lab claims before submission.
Thirty minutes, no deck and no fee. We look at what is sitting past 90 days and where your denials cluster, and you leave knowing what is recoverable, what we would work first, and what it would cost.
Book a Billing Review%20(1).avif)
